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Aim. To characterize subjects with a nonpositive insulinogenic index and longitudinally observe changes in their glucose tolerance.
Subjects and Methods. A historical cohort study was conducted using data from the medical checkups of public school workers.
Indices of insulin secretion and insulin sensitivity derived from oral glucose tolerance test (OGTT) and the incidences of
diabetes and impaired glucose tolerance (IGT) were compared among subgroups of subjects with diﬀerent insulinogenic index
(change in insulin/change in glucose over the ﬁrst 30min on the OGTT). Results. Of the 1464 nondiabetic subjects at baseline,
72 (4.9%) subjects had a nonpositive insulinogenic index: 42 of those subjects had a nonpositive glucose response (ΔGlu0–30≤ 0)
and 30 had a nonpositive insulin response (ΔIns0–30≤ 0). Compared with subjects who had normal glucose tolerance (NGT)
with insulinogenic index≥ 0.4, subjects with a nonpositive glucose response had a higher ﬁrst-phase Stumvoll and lower
incidences of diabetes and IGT based on a log-rank test (p < 0 05), whereas subjects with a nonpositive insulin response
had lower indices of insulin secretion and a higher incidence of diabetes (p < 0 05). Conclusions. These results demonstrate
that in the ﬁrst 30min on the OGTT, subjects with a nonpositive insulinogenic index due to a nonpositive glucose response
(ΔGlu0–30≤ 0) had a lower risk for future diabetes and that subjects with nonpositive insulin response (ΔIns0–30≤ 0) had a
higher risk for future one.
1. Introduction
Insulinogenic index (change in insulin/change in glucose
over the ﬁrst 30min after the load) on the oral glucose toler-
ance test (OGTT) has been widely used as an index of early
phase insulin secretion in clinical studies [1–4]. It is highly
correlated with the acute insulin response (AIR) on intrave-
nous glucose tolerance test (IVGTT) and is considered a
reasonable surrogate [5, 6]. Measuring insulinogenic index
has several advantages; it involves less complex protocols,
needs less costs, and utilizes a physiological route of glucose
administration [7, 8]. Simpler methods for the assessment
of insulin secretion are those based on basal glucose and
insulin concentrations, such as HOMA-beta [9], but fasting
levels cannot provide insight into the secretory response of
beta cells to rising glucose concentrations [8]. Indeed, insuli-
nogenic index or its composite with insulin sensitivity (oral
disposition index) has been demonstrated to be predictive
of type 2 diabetes, independent of fasting plasma glucose in
diﬀerent populations [4, 10–12].
Sometimes, however, a small number of subjects in
general populations exhibit a nonpositive insulinogenic
index due to either a decrement in insulin or in glucose value
30min after glucose ingestion from fasted states [13]. Most
studies, including ours, exclude them from the main analysis
[14]. Abdul-Ghani et al. have reported a lower risk for future
diabetes in individuals whose plasma glucose concentrations
returned to equal to or below fasting levels within 30min
compared with those who required longer time to return
their plasma glucose to fasting levels [15]. Besides the report
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by Abdul-Ghani et al., there has been no report on the clini-
cal characteristics and the risk for future diabetes in subjects
with a nonpositive insulinogenic index.
The aim of this study, therefore, was to characterize
subjects with a nonpositive insulinogenic index and longi-
tudinally observe changes in their glucose tolerance.
2. Methods
2.1. Study Participants. A historical cohort study was con-
ducted using data from the medical checkups of public
school employees collected at Hokuriku Central Hospital
[14]. During April 2006 and March 2010 (baseline period),
2340 employees underwent an OGTT at a medical checkup
[16]. If employees received more than one checkup during
the baseline period, the initial checkup data were used. After
those who had fasting plasma glucose≥ 126mg/dL and/or 2 h
plasma glucose≥ 200mg/dL (n = 85), those who had HbA1c
values≥ 6.9% (52mmol/mol) (n = 42), those who had under-
gone gastrectomy (n = 32), those who were taking steroids
(n = 1) or anticancer drugs (n = 1), those who or had any
missing data (n = 18) were excluded, 2161 nondiabetic indi-
viduals were selected. Of these, 1464 individuals repeated
checkups at least once until March 2016 and comprised our
study sample. The remaining 697 participants did not have
a repeat checkup, yielding a follow-up rate of 67.7%. If the
subjects developed diabetes, the follow-up ended at that time.
An OGTT was performed at all checkups during the follow-
up period; however, within the last two years (April 2014 to
March 2016), an OGTT was performed on 1191 participants
and the measurement of fasting plasma glucose only was per-
formed in the remaining 273 participants for ﬁnancial rea-
sons. Information on smoking and drinking habits and a
medical history were obtained via a questionnaire. Partici-
pants were considered current smokers if they smoked at
least one cigarette per day. Alcohol use was deﬁned by the
number of days per week it was consumed, regardless of
the amount. Informed consent was obtained by an opt-out
method, and the institutional review board of the Kanazawa
University approved the study protocol on June 21, 2017
(IRB number 2497-1); the study protocol conforms to the
provisions of the Declaration of Helsinki. The study was
registered on the University Hospital Medical Information
Network Clinical Trials Registry (UMIN-CTR, http://www.
umin.ac.jp/ctr, UMIN ID: UMIN000017662).
2.2. Blood Sampling and Assay. All evaluations were per-
formed at the Health Check Department of the Hokuriku
Central Hospital. Participants were asked to visit the hospital
between 8:00 a.m. and 9:00 a.m. after an overnight fast. At the
baseline visit, an OGTT (75 g dextrose monohydrate in
250mL water) with 0, 30, 60, and 120min sampling to deter-
mine plasma glucose and insulin concentrations was
performed on all participants [16]. Plasma glucose was
assessed using the glucose oxidase method (Automatic Glu-
cose Analyzer ADAMS Glucose GA-1160, Arkray, Kyoto,
Japan) at the hospital laboratory. Insulin concentration
assays were performed by the chemiluminescence immuno-
assay method at a commercial laboratory (BML Inc., Tokyo,
Japan), with an intra-assay coeﬃcient of variation (CV) of
2.4–3.2% based on 10 replicates of 3 diﬀerent samples.
Height and weight were measured, and body mass index
(BMI) was calculated by dividing weight (kg) by height
squared (m2).
2.3. Calculations of Indices of Insulin Secretion and Insulin
Sensitivity. The indices of insulin secretion used in this
study were as follows: insulinogenic index= (Ins30− Ins0)/
(Gluc30−Gluc0) or ΔIns0–30/ΔGlu0–30, where Insy and Gluy
represent values at time (y: min) during the OGTT [5, 6];
the ratio of area under the curve (AUC) for insulin to
AUC for glucose for the speciﬁc time frame, which was calcu-
lated by applying the trapezoid rule; ﬁrst-phase Stum-
voll = 1283+1.829× Ins30–138.7×Glu30+ 3.772× Ins0; and
second-phase Stumvoll = 286+ 0.416× Ins30–25.94×Glu30+
0.926× Ins0 [17]. The indices of insulin sensitivity were as
follows: Matsuda insulin sensitivity index (ISI) = 10,000/
(Glu0× Ins0×Glu120× Ins120)0.5 [18] and homeostatic model
assessment of insulin resistance (HOMA-IR) =Glu0× Ins0/
405 [9]. We used diﬀerent units for glucose concentration
and insulin concentration in calculating each index, as
described in Table 1.
2.4. Statistical Analysis. The data are presented as the mean
± standard deviation or median with interquartile ranges
for continuous variables or as a frequency for categorical var-
iables. Continuous variables were compared using one-way
analysis of variance (ANOVA) or Kruskal-Wallis test, and
categorical values were compared using a χ2 test, with a Bon-
ferroni correction for multiple comparisons. The participants
were classiﬁed by their insulinogenic index at 0.4 because this
threshold was adopted by the Japan Diabetes Society to iden-
tify individuals at a high risk of progression to diabetes [19].
Participants were further classiﬁed by their glucose tolerance
using the criteria of the American Diabetes Association
(ADA) [20]; subjects were categorized as having NGT (fast-
ing plasma glucose< 100mg/dL and 2h plasma glucose<
140mg/dL), impaired fasting glucose (IFG) (fasting plasma
glucose = 100–125mg/dL), and impaired glucose tolerance
(IGT) (2-hour plasma glucose = 140–199mg/dL). Among
groups, indices of insulin sensitivity and insulin secretion
were compared using analysis of covariance (ANCOVA)
with age, gender, and BMI as covariates. Insulinogenic index
and HOMA-IR were log-transformed using the natural log
prior to analysis to reduce skewness; the transformed values
produced a good ﬁt to normal distribution. Finally, the pro-
gression to diabetes deﬁned as fasting plasma glucose≥
126mg/dL, 2-hour plasma glucose≥ 200mg/dL, and/or tak-
ing treatments for diabetes or to IGT among subjects grouped
by insulinogenic index was compared by the Kaplan-Meier
method. The analysis of the progression to IGT was per-
formed in 982 out of the 1169 NGT subjects at baseline,
because the remaining 187 NGT subjects did not receive
an OGTT at follow-up. A p value of < 0.05 was consid-
ered statistically signiﬁcant. All analyses were conducted
using SPSS software version 24.0 for Windows (SPSS Inc.,
Chicago, USA).
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3. Results
Study subjects were 1464 nondiabetic individuals with a
mean age of 52.0 years and a mean BMI of 23.9 kg/m2 at
baseline. There were 42 (2.9%) subjects whose plasma glu-
cose concentrations fell equal to or below their fasting levels
at 30min (ΔGlu0–30≤ 0) and 30 (2.0%) subjects whose insulin
concentrations fell equal to or below the fasting levels at
30min after the oral glucose load (ΔIns0–30≤ 0). Three sub-
jects with double nonpositive values, resulting in a positive
insulinogenic index, were excluded from the following
analysis. As shown in Figure 1, subjects with ΔIns0–30≤ 0
increased their insulin concentrations at 120min from
30min, while those with ΔGlu0–30≤ 0 got to return their
insulin concentrations at 120min. As shown in Table 2, sub-
jects with ΔGlu0–30≤ 0 included a lower proportion of men
and had a lower BMI and lower glucose and insulin concen-
trations during OGTT, compared with subjects with insuli-
nogenic index≥ 0.4 (p < 0 05). Subjects with ΔIns0–30≤ 0
had a higher BMI and higher glucose and fasting insulin
concentrations compared with subjects with ΔGlu0–30≤ 0
(p < 0 05). Subjects with ΔGlu0–30≤ 0 had a signiﬁcantly
higher proportion of NGT (92.9%) compared with the
other three groups listed in Table 2 (p < 0 05).
To evaluate insulin secretion and insulin sensitivity on
the basis of the OGTT, we classiﬁed subjects with nonpo-
sitive insulinogenic index into 2 groups (i.e., ΔGlu0–30≤ 0
and ΔIns0–30≤ 0) and those with positive insulinogenic
index into 2 groups as well [with subgroups] (i.e., NGT
[insulinogenic index≥ 0.4 or <0.4] and IFG and/or IGT
[insulinogenic index≥ 0.4 or <0.4]) (Table 1). In subjects
with ΔGlu0–30≤ 0, indices of insulin secretion such as
AUC(Ins30)/AUC(Glu30) and AUC(Ins120)/AUC(Glu120)
were not signiﬁcantly decreased and ﬁrst-phase Stumvoll
was increased compared with NGT with insulinogenic
index≥ 0.4. In subjects with ΔIns0–30≤ 0, all indices of
insulin secretion examined were signiﬁcantly decreased
compared with IFG and/or IGT as well as NGT with insu-
linogenic index≥ 0.4. Matsuda ISI and HOMA-IR were not
signiﬁcantly diﬀerent in subgroups with nonpositive insuli-
nogenic index compared with NGT with insulinogenic
index≥ 0.4. These indices were estimated after adjustments
for gender, age, and BMI; however, the results were essen-
tially the same before the adjustments (data not shown).
The progression to diabetes (Figure 2) or to IGT
(Figure 3) was assessed among diﬀerent subgroups by
insulinogenic index. In subjects with ΔGlu0–30≤ 0, there
was no progression to diabetes nor to IGT during a mean
follow-up period of 5.6 years, which was signiﬁcantly less
than NGT with insulinogenic index≥ 0.4 by log-rank test
(p < 0 05). In subjects with ΔIns0–30≤ 0, the incidence of
diabetes was signiﬁcantly higher compared with NGT
with insulinogenic index≥ 0.4 (P < 0 05) while that of IGT
was not statistically diﬀerent by log-rank test. In compari-
son between subjects with ΔGlu0–30≤ 0 and those with
ΔIns0–30≤ 0, the incidences of diabetes and of IGT were
signiﬁcantly diﬀerent (p = 0 016 and p < 0 001, resp.).
4. Discussion
In this study, subjects with a nonpositive insulinogenic index
were characterized based on insulin secretion and insulin
sensitivity and diabetes and IGT incidences were compared
with subjects who had a positive insulinogenic index.
Although the prevalence of nonpositive insulinogenic index
was low in agreement with prior studies investigating West-
ern cohorts [13], this is the ﬁrst study in Asian populations
that longitudinally observed the future incidence of glucose
intolerance in subjects with a nonpositive insulinogenic
index. The ﬁndings of the current study could be useful for
Insulinogenic index ≥ 0.4
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Figure 1: Plasma glucose and insulin concentrations on the OGTT among subgroups of subjects with a diﬀerent insulinogenic index as
presented as median values.
4 Journal of Diabetes Research
estimating the risk for diabetes when clinicians encounter
subjects with a nonpositive insulinogenic index.
The prevalence of a nonpositive insulinogenic index
was 4.9% (72/1464) in nondiabetic subjects in this study.
The prevalence in other cohorts has been reported as
8.2% in the San Antonio Heart Study, 3.4% in the Genet-
ics of NIDDM Study, and 2.5% in the Japanese American
Community Diabetes Study [13]. There were two reasons
for a nonpositive insulinogenic index: a nonpositive glucose
response (ΔGlu0–30≤ 0) and a nonpositive insulin response
(ΔIns0–30≤ 0) after a glucose load. The former included a
higher proportion of NGT than the latter in this study
(92.9% versus 46.7%), which is in agreement with the
results from the San Antonio Heart Study (81.4% versus
11.8%). We conﬁrmed and extended the observation that a
nonpositive insulinogenic index occurs at a given frequency
in Japanese populations.
Subjects with a nonpositive glucose response 30min after
a glucose load had similar or even higher insulin secretion
compared with NGT with insulinogenic index≥ 0.4 and a
lower risk for future deterioration of glucose tolerance.
Abdul-Ghani et al. have reported that individuals whose
plasma glucose concentrations return to equal to or below
the fasting levels by 30min after a glucose load showed the
highest insulin sensitivity, the highest insulin secretion, and
the lowest risk for future diabetes, compared with those
who required >30min for their plasma glucose to return to
fasting levels in Mexican Americans [15] and Caucasians
[21]. Of note, the insulinogenic index could not be calculated
due to nonpositive glucose response in their study, so they
assessed insulin secretion by AUC (Ins30)/AUC(Glu30),
which was also applied in this study. The subjects with a non-
positive glucose response are likely to be highly eﬃcient in
disposing glucose and in maintaining normal glucose
homeostasis following a glucose load.
Subjects with a nonpositive insulin response 30min
after the glucose load had the lowest insulin secretion
among diﬀerent groups of the insulinogenic index. This
group comprised of more IFG and/or IGT and showed a
higher BMI compared with the abovementioned subjects
with a nonpositive glucose response. In the study exam-
ining the acute (ﬁrst-phase) insulin response to intrave-
nous glucose, a paradoxically nonpositive insulin response
had also been observed in subjects with fasting hyperglyce-
mia [22]. A nonpositive insulin response at 30min on the
OGTT may reﬂect an impairment of early insulin response,
which is one of the primary pathophysiologic changes of
type 2 diabetes.
Of note, insulin levels at 120min in subjects with a
nonpositive insulin response were similar to other groups,
Table 2: Baseline characteristics by level of the insulinogenic index.









Age (years) 51.6± 7.0 52.9± 6.7∗ 50.6± 7.1 50.2± 8.5
Male gender (%) 65.3 79.5∗ 42.9∗† 63.3
Body mass index (kg/m2) 24.3± 3.3 23.6± 2.9∗ 22.4± 2.7∗ 24.8± 4.3‡
Fasting plasma glucose (mg/dL) 92/96/101 94/99/106∗ 88/91/95∗† 92/98/108‡
30min plasma glucose (mg/dL) 126/143/162 150/168/186∗ 76/81/88∗† 132/163/182‡
1-hour plasma glucose (mg/dL) 106/131/159 146/178/205∗ 72/92/101∗† 112/151/192∗‡
2-hour plasma glucose (mg/dL) 96/109/126 105/123/146∗ 81/92/111∗† 90/120/142‡
Fasting insulin (μIU/mL) 3.1/4.3/6.2 2.6/3.3/4.3∗ 2.8/4.2/4.7 2.4/3.3/6.2
30min insulin (μIU/mL) 29.2/40.2/58.3 13.7/19.1/24.1∗ 13.7/20.1/32.9∗ 0.8/1.4/2.1∗†‡
120min insulin (μIU/mL) 16.3/24.6/39.7 14.5/21.5/34.9∗ 9.1/15.3/21.9∗ 10.6/23.0/39.1
HbA1c (%) 5.2± 0.3 5.3± 0.4∗ 5.1± 0.3† 5.3± 0.4
Glucose tolerance
Normal glucose tolerance (%) 62.2 39.4∗ 92.9∗† 46.7‡
Impaired fasting glucose (%) 32.1 49.8 7.2∗† 43.3
Impaired glucose tolerance (%) 13.2 30.9∗ 2.4 30.0
Current smokers (%) 17.5 25.0∗ 19.0 20.0
Drinkers (%) 59.9 71.3∗ 42.9† 63.3
Antihypertensive medications (%) 13.6 14.6 7.1 10.0
Lipid-lowering medications (%) 6.9 7.3 2.4 6.7
Data are expressed as mean ± standard deviation, 25/50/75th percentile values, or %. Characteristics among groups were compared using one-way ANOVA for
continuous variables and chi-square tests for categorical variables with Bonferroni correction for multiple comparisons. ∗p < 0 05 compared to insulinogenic
index ≥ 0.4, †p < 0 05 compared to insulinogenic index < 0.4, ‡p < 0 05 compared to ΔGlu0–30 ≤ 0. ΔGlu0–30 and ΔIns0–30, change in glucose and in insulin,
respectively, over the ﬁrst 30min on the oral glucose tolerance test.
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indicating that insulin secretion was delayed but preserved
(Figure 1). Recently, Lorenzo et al. have reported that
indices of insulin secretion derived from the late OGTT
period as well as the early period (e.g., insulinogenic
index) independently predict the incidence of diabetes
from the San Antonio Study [23]. Although the late insu-
lin secretion may keep the subjects with a nonpositive
insulin response from the development of diabetes, they
are likely to have a higher risk of diabetes compared with
the IFG and/or IGT with insulinogenic index≥ 0.4.
We evaluated several OGTT-based indices of insulin
secretion. When glucose is administered intravenously, the
insulin response to a hyperglycemic stimulation is biphasic
[24]; plasma insulin concentrations increase rapidly to a peak
at 2 to 4min, decrease within 10 to 15min (ﬁrst-phase insulin
release), and gradually increase over 120min (second-phase
insulin release) [25]. First-phase Stumvoll has been validated
against this ﬁrst-phase insulin release on hyperglycemic
clamp test [26]. Although measurements of plasma insulin
are ordinarily performed at 30min on the OGTT, this time
point may be too late to capture the early insulin response
in some subjects with a prompt secretory response to glucose
stimulation. In these subjects, the ﬁrst burst of insulin
secreted into the portal vein would suppress hepatic glucose
production and decrease their plasma glucose equal to or
below the fasting levels by 30min after the glucose load.
The strength of our study is the longitudinal design,
which allows for a comparison of future risk for diabetes
among groups by insulinogenic index. However, several
limitations of this study should be considered. First, the
Positive insulinogenic index Nonpositive insulinogenic index
IFG and/or IGTNGT
ΔGlu0−30 ≤ 0
(n = 42) 
ΔIns0−30 ≤ 0
(n = 30) 





Incidence (%) 6 (1.2) 7 (3.2) 25 (8.0)⁎ 69 (20.3)⁎ 0⁎ 4 (13.3)⁎
5.4 5.2 4.9 4.6 5.6 4.7
0.2 0.6 1.6 4.4⁎ 0.0⁎ 2.8⁎
⁎Signiﬁcantly diﬀerent from NGT with insulinogenic index  ≥ 0.4 by log-rank test (p < 0.001). #Signiﬁcantly diﬀerent between
Δ Glu0−30 ≤ 0 and Δ Ins0−30 ≤ 0 (P = 0.016). 





























Figure 2: Cumulative incidence of diabetes by the Kaplan-Meier method among groups by insulinogenic index.
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follow-up rate of the subjects was 67.7%. Subjects who
missed checkups during the follow-up period might be less
conscious about their health, which biased the study
subjects toward metabolically healthy people. However,
baseline characteristics including BMI, glucose, and insulin
concentrations between the subjects who were and were
not followed were not signiﬁcantly diﬀerent. Second, mea-
surements of C-peptide were not performed. C-peptide has
been utilized to assess the insulin secretory function of
beta cells because it is not degraded by the liver and thus
represents prehepatic insulin secretion [27]. However, in
estimation of the prehepatic insulin secretion, the calcula-
tion from insulin and that from C-peptide has been shown
to be highly correlated (R2 = 0.75, p < 0 001) [28]. Third,
the measurement of plasma glucose concentrations relied
on a single OGTT, which is known to have within-
subject variability [29].
In conclusion, a nonpositive insulinogenic index occurs
at a given frequency in Japanese populations, due to a nonpo-
sitive glucose response or due to a nonpositive insulin
response 30min after the load. The former is eﬃcient in dis-
posing glucose and has a lower risk for future diabetes, while
the latter showed a lower early insulin response and has a
higher risk for future diabetes.
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